183 related articles for article (PubMed ID: 37108661)
21. Novel naphthyloxy derivatives - Potent histamine H
Łażewska D; Kaleta M; Hagenow S; Mogilski S; Latacz G; Karcz T; Lubelska A; Honkisz E; Handzlik J; Reiner D; Satała G; Filipek B; Stark H; Kieć-Kononowicz K
Bioorg Med Chem; 2018 May; 26(9):2573-2585. PubMed ID: 29681486
[TBL] [Abstract][Full Text] [Related]
22. New lead elements for histamine H
Espinosa-Bustos C; Frank A; Arancibia-Opazo S; Salas CO; Fierro A; Stark H
Bioorg Med Chem Lett; 2018 Sep; 28(17):2890-2893. PubMed ID: 30025902
[TBL] [Abstract][Full Text] [Related]
23. Refined docking as a valuable tool for lead optimization: application to histamine H3 receptor antagonists.
Levoin N; Calmels T; Poupardin-Olivier O; Labeeuw O; Danvy D; Robert P; Berrebi-Bertrand I; Ganellin CR; Schunack W; Stark H; Capet M
Arch Pharm (Weinheim); 2008 Oct; 341(10):610-23. PubMed ID: 18816585
[TBL] [Abstract][Full Text] [Related]
24. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
25. Novel histamine H3-receptor antagonists with benzyl ether structure or related moieties: synthesis and structure-activity relationships.
Hüls A; Purand K; Stark H; Reidemeister S; Ligneau X; Arrang JM; Schwartz JC; Schunack W
Arch Pharm (Weinheim); 1996; 329(8-9):379-85. PubMed ID: 8915097
[TBL] [Abstract][Full Text] [Related]
26. Anticonvulsant effects of isomeric nonimidazole histamine H
Sadek B; Saad A; Schwed JS; Weizel L; Walter M; Stark H
Drug Des Devel Ther; 2016; 10():3633-3651. PubMed ID: 27853355
[TBL] [Abstract][Full Text] [Related]
27. Histamine H3-receptor inverse agonists as novel antipsychotics.
Ito C
Cent Nerv Syst Agents Med Chem; 2009 Jun; 9(2):132-6. PubMed ID: 20021346
[TBL] [Abstract][Full Text] [Related]
28. Central Histamine, the H
Díaz NF; Flores-Herrera H; García-López G; Molina-Hernández A
CNS Neurol Disord Drug Targets; 2019; 18(7):516-522. PubMed ID: 31269888
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
[TBL] [Abstract][Full Text] [Related]
30. Search for new multi-target compounds against Alzheimer's disease among histamine H
Bajda M; Łażewska D; Godyń J; Zaręba P; Kuder K; Hagenow S; Łątka K; Stawarska E; Stark H; Kieć-Kononowicz K; Malawska B
Eur J Med Chem; 2020 Jan; 185():111785. PubMed ID: 31669851
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Potential of Histamine H3 Receptors in Substance Use Disorders.
Di Ciano P; Hendershot CS; Le Foll B
Curr Top Behav Neurosci; 2022; 59():169-191. PubMed ID: 35704272
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Potential, Dual-Active Histamine H
Kuder KJ; Kotańska M; Szczepańska K; Mika K; Reiner-Link D; Stark H; Kieć-Kononowicz K
Molecules; 2021 Apr; 26(8):. PubMed ID: 33921144
[TBL] [Abstract][Full Text] [Related]
33. Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists.
Nirogi R; Shinde A; Tiriveedhi V; Kota L; Saraf SK; Badange RK; Mohammed AR; Subramanian R; Muddana N; Bhyrapuneni G; Abraham R
Eur J Med Chem; 2016 Jan; 108():655-662. PubMed ID: 26731168
[TBL] [Abstract][Full Text] [Related]
34. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
[TBL] [Abstract][Full Text] [Related]
35. Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs.
Lipani L; Odadzic D; Weizel L; Schwed JS; Sadek B; Stark H
Eur J Med Chem; 2014 Oct; 86():578-88. PubMed ID: 25218907
[TBL] [Abstract][Full Text] [Related]
36. Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives.
Apelt J; Grassmann S; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
Pharmazie; 2005 Feb; 60(2):97-106. PubMed ID: 15739896
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic approach of histamine H3 receptors in obesity.
Masaki T; Yoshimatsu H
Recent Pat CNS Drug Discov; 2007 Nov; 2(3):238-40. PubMed ID: 18221234
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
39. [The roles of histamine H3 receptors in the behavioral disorders and neuropsychopharmacological aspects of its ligands in the brain].
Onodera K; Miyazaki S
Nihon Yakurigaku Zasshi; 1999 Aug; 114(2):89-106. PubMed ID: 10511950
[TBL] [Abstract][Full Text] [Related]
40. Histamine H3 receptor antagonists go to clinics.
Sander K; Kottke T; Stark H
Biol Pharm Bull; 2008 Dec; 31(12):2163-81. PubMed ID: 19043195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
